TTM
$2.12B
YoY change
+24.8%
5Y CAGR
+14.1%
Peak year (2025)
$1.91B
Cumulative EBITDA
$15.78B
EBITDA history chart for ResMed (RMD) from 1993 to 2025
Latest: $1.91B
EBITDA growth chart for ResMed (RMD) from 1993 to 2025
Latest: +24.8%
EBITDA history table for ResMed (RMD) from 1993 to 2025
| 2025 | $1.91B | +24.8% | +$379.83M | ||
| 2024 | $1.53B | +12.9% | +$174.74M | ||
| 2023 | $1.36B | +15.5% | +$182.16M | ||
| 2022 | $1.18B | +6.6% | +$72.77M | ||
| 2021 | $1.10B | +11.5% | +$113.44M | ||
| 2020 | $990.43M | +40.3% | +$284.63M | ||
| 2019 | $705.80M | +3.8% | +$25.57M | ||
| 2018 | $680.22M | +19.6% | +$111.33M | ||
| 2017 | $568.89M | +8.8% | +$46.17M | ||
| 2016 | $522.72M | +8.4% | +$40.42M | ||
| 2015 | $482.29M | -0.5% | −$2.58M | ||
| 2014 | $484.87M | +3.2% | +$15.08M | ||
| 2013 | $469.79M | +11.2% | +$47.20M | ||
| 2012 | $422.59M | +12.9% | +$48.26M | ||
| 2011 | $374.32M | +16.2% | +$52.17M | ||
| 2010 | $322.15M | +69.3% | +$131.84M | ||
| 2009 | $190.31M | -7.1% | −$14.52M | ||
| 2008 | $204.83M | +127.2% | +$114.67M | ||
| 2007 | $90.16M | -48.2% | −$83.88M | ||
| 2006 | $174.04M | +27.1% | +$37.14M | ||
| 2005 | $136.90M | +60.4% | +$51.54M | ||
| 2004 | $85.36M | +6.9% | +$5.54M | ||
| 2003 | $79.82M | -295.5% | +$120.66M | ||
| 2002 | −$40.84M | -178.3% | −$93.00M | ||
| 2001 | $52.16M | +32.4% | +$12.78M | ||
| 2000 | $39.39M | +31.7% | +$9.49M | ||
| 1999 | $29.90M | +42.4% | +$8.90M | ||
| 1998 | $21.00M | +92.7% | +$10.10M | ||
| 1997 | $10.90M | +122.4% | +$6.00M | ||
| 1996 | $4.90M | +44.1% | +$1.50M | ||
| 1995 | $3.40M | +112.5% | +$1.80M | ||
| 1994 | $1.60M | +77.8% | +$700.00K | ||
| 1993 | $900.00K | — | — |
- 2025$1.91B+24.8%
- 2024$1.53B+12.9%
- 2023$1.36B+15.5%
- 2022$1.18B+6.6%
- 2021$1.10B+11.5%
- 2020$990.43M+40.3%
- 2019$705.80M+3.8%
- 2018$680.22M+19.6%
- 2017$568.89M+8.8%
- 2016$522.72M+8.4%
- 2015$482.29M-0.5%
- 2014$484.87M+3.2%
- 2013$469.79M+11.2%
- 2012$422.59M+12.9%
- 2011$374.32M+16.2%
- 2010$322.15M+69.3%
- 2009$190.31M-7.1%
- 2008$204.83M+127.2%
- 2007$90.16M-48.2%
- 2006$174.04M+27.1%
- 2005$136.90M+60.4%
- 2004$85.36M+6.9%
- 2003$79.82M-295.5%
- 2002−$40.84M-178.3%
- 2001$52.16M+32.4%
- 2000$39.39M+31.7%
- 1999$29.90M+42.4%
- 1998$21.00M+92.7%
- 1997$10.90M+122.4%
- 1996$4.90M+44.1%
- 1995$3.40M+112.5%
- 1994$1.60M+77.8%
- 1993$900.00K—
EBITDA values are taken from ResMed's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About EBITDA at ResMed (RMD)
According to ResMed's latest reported financial statements, the company's current EBITDA (TTM) is $2.12B. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a common proxy for operating cash generation that strips out non-cash charges (depreciation and amortization) and capital structure effects (interest, taxes). Useful for comparing companies with different leverage and asset bases — see operating income and net income for fully GAAP figures.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
ResMed (RMD) most recent annual EBITDA stands at $1.91B (2025) – grew 24.8% year-over-year.
Over 2020–2025 (5 years), ResMed EBITDA expanded at a +14.1% compound annual rate, sustaining 10 straight years of year-over-year growth.
$1.91B stands as the all-time-high annual EBITDA, posted in 2025, against a low of −$40.84M during 2002.
ResMed EBITDA by Year
ResMed EBITDA 2025: $1.91B
ResMed posted EBITDA of $1.91B in 2025, grew 24.8% from 2024. This figure represents the highest annual value in the available history.
ResMed EBITDA 2024: $1.53B
In 2024, ResMed reported EBITDA of $1.53B, grew 12.9% from 2023.
ResMed EBITDA 2023: $1.36B
ResMed EBITDA in 2023 was $1.36B, grew 15.5% from 2022.
ResMed EBITDA 2022: $1.18B
2022's EBITDA for ResMed came in at $1.18B, grew 6.6% from 2021.
ResMed EBITDA 2021: $1.10B
ResMed EBITDA in 2021 was $1.10B.
See more financial history for ResMed (RMD).
Sector peers by EBITDA
Healthcare peers of ResMed (RMD), ranked by their latest EBITDA
| $41.05B | |
| $28.26B | |
| $27.94B | |
| $24.43B | |
| $23.06B | |
| $19.83B | |
| $17.63B | |
| $16.90B |
- $41.05B
- $28.26B
- $27.94B
- $24.43B
- $23.06B
- $19.83B
- $17.63B
- $16.90B
Frequently asked questions
ResMed (RMD) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation